Italiano Farmacia on line: comprare cialis senza ricetta, acquistare viagra internet.

Microsoft word - delivery after previos cs birth 16.3.06.doc

Guideline No…
pÉííáåÖ=ëí~åÇ~êÇë=íç=áãéêçîÉ=ïçãÉåÛë=ÜÉ~äíÜ DELIVERY AFTER PREVIOUS CAESAREAN BIRTH

1. Aim

To provide evidence-based information on the management of women undergoing either trial
of vaginal birth after previous caesarean section (trial of VBAC) or elective repeat caesarean
section (ERCS). This guideline is primarily aimed at the management of women with an
uncomplicated term singleton pregnancy with a history of single previous lower segment
caesarean section.
2. Introduction and background

After having had a previous section, women may opt for either trial of VBAC or ERCS.
There is widespread public and professional concern about the rising rates of caesarean
section 1, which has contributed to an increased obstetric population with a history of prior
caesarean and increased rates of repeat caesarean delivery 2-5. Trial of VBAC has been
advocated as a safe method to reduce the number of caesarean sections performed. In the
RCOG’s National Sentinel Caesarean Section Audit (NSCCA) of 2000 6, 50% of women with
a previous caesarean section attempted VBAC, and the success rate was 64%.
Recent observational studies have shown that maternal and perinatal morbidity and perinatal
mortality are higher in women undergoing trial of VBAC compared to ERCS. These factors,
along with medico-legal fears, have led to a recent decline in clinicians offering, and women
accepting, trial of VBAC delivery 2-5 This guideline presents the best available evidence to
facilitate antenatal counselling in women with prior caesarean delivery and intrapartum
management of women undergoing trial of VBAC.

3. Identification and assessment of evidence

Electronic searches were performed in MEDLINE (Ovid version 1996-January 2006),
EMBASE (Ovid version 1996-January 2006) using relevant medical subject headings and
text words. Evidence based reviews and guidance from ACOG7;8, SOGC 9 , ARHQ USA 10,
and The Cochrane Library (2006) 11 were identified and used in the development of this
guideline. The definitions of the types of evidence used in this guideline originate from the
US Agency for Health Care Research and Quality. Where possible, recommendations are
based on and explicitly linked to the evidence that supports them. Areas lacking evidence are
highlighted and annotated as ‘good practice points’.
4. Definition of terms used in this guideline
Trial of VBAC:
Trial of VBAC (vaginal birth after caesarean) refers to any woman who has
experienced a prior caesarean birth who plans to deliver vaginally rather than by elective
repeat caesarean section (ERCS).
Successful and unsuccessful trial of VBAC:
A spontaneous or assisted vaginal delivery in a
woman undergoing trial of VBAC indicates a successful trial. Delivery by emergency
caesarean section during such an attempt indicates an unsuccessful trial of VBAC.
Uterine rupture : defined as disruption of the full thickness of the uterine muscle that
breaches the uterine serosa. Uterine dehiscence is defined as disruption of the uterine muscle
with intact serosa.

Term Perinatal mortality: combined number of stillbirths (antepartum and intrapartum) and
neonatal deaths (death of a live born infant from birth to age 28 days) per 10,000 live births
and stillbirths, excluding deaths due to fetal malformation.

Term Delivery-related perinatal death
: combined number of intrapartum stillbirths and
neonatal deaths per 10,000 stillbirths and live births, excluding deaths due to fetal
malformation.
Neonatal respiratory morbidity: combined rate of transient tachypnoea of the newborn
(TTN) and respiratory distress syndrome (RDS).
5. Limitations of data used in guideline

There are no RCTs comparing planned trial of VBAC against planned ERCS 11. Evidence for
these interventions is obtained mainly from retrospective non-randomised studies.
Furthermore, many of the main outcomes of interest are relatively uncommon. Adequately
powered studies require large numbers and these frequently rely on routinely collected data.
Consequently, many studies have limitations in terms of definition of exposures and
outcomes, ascertainment bias and selection bias. Furthermore, the consequent inter-study
heterogeneity undermines reliable meta-analyses12;13. A recently published study by the
National Institute of Child Health and Human Development (NICHD) Maternal–Fetal
Medicine Units Network14 has overcome many of these shortcomings by having a large
sample size, a prospective cohort design and utilising standardised definitions for assessing
outcomes. A major issue in the interpretation of that report is, however, that the groups being
delivered by ERCS included all women, including those in whom vaginal delivery was
relatively or absolutely contraindicated. While this study provides useful estimates of the
absolute risk of adverse events related to attempted VBAC, the risk of adverse outcome
among the ERCS group may be an over-estimate of the risk for women who are eligible for
VBAC.

6. Suitability for trial of VBAC
Any woman with a prior history of one uncomplicated low transverse caesarean section,
in an otherwise uncomplicated pregnancy at term, with no contraindication for vaginal
delivery, may be offered a trial of VBAC.

There is insufficient evidence on whether maternal or neonatal outcomes are significantly influenced by the number of prior caesarean deliveries or type of prior uterine scar 14-18. Nonetheless, due to high absolute risks of uterine rupture, trial of VBAC is absolutely contraindicated in women with:- • Previous uterine rupture • Previous classical caesarean section
• More than two previous caesarean deliveries
A number of other variants are associated with an increased risk of uterine rupture. These
include: women with prior inverted T or J incision (1.9% rupture risk)14, women with prior
low vertical incision (2% rupture risk)14 and women with two previous low transverse
caesarean deliveries (1.7%-3.7% rupture risk; 62%-75% VBAC success rate 16;19;20). Women
who wish to attempt VBAC despite previous complex uterine incisions or more than one
previous caesarean section should be counselled by a consultant and risk analysis made of the
indication for - and the nature of - the previous surgery.
7. Antenatal counselling
The antenatal counselling of women eligible for VBAC should be documented in the
notes and supplemented with administration of a patient information leaflet.

Any woman who has experienced a prior caesarean birth should be counselled about the
maternal and perinatal risks and benefits of trial of VBAC and ERCS when deciding the
mode of delivery. The key issues to include in the discussion are listed below. The risks and
benefits should be discussed in the context of the woman's individual circumstances,
including her personal motivation to achieve vaginal birth, her attitudes towards the risk of
rare but serious adverse outcomes, her plans for future pregnancies and her chance of a
successful attempt (principally whether she has previously had a vaginal birth - see below).
Women considering trial of VBAC should be counselled that there is a high chance of
success in most cases (success rates of 72%-76%)

Individual studies report success rates of 72%-76% 14;21;22 for trial of VBAC, which concurs
with pooled rates derived by systematic and summative reviews 12;23;24. Maternal adverse
events (uterine rupture, hysterectomy, transfusion and endometritis) are more common in
women with failed VBAC compared with both successful VBAC and ERCS 14;22.

A number of factors are associated with successful trial of VBAC. Previous vaginal delivery,
particularly previous VBAC, is the best single predictor of a successful trial of VBAC and is
associated with an approximately 90% success rate 25-27. The likelihood of success is lowered
if labour is induced, BMI>30 and previous caesarean indication was for dystocia 25. When all
these factors are present, VBAC is achieved in only 40% of cases 25. Trial of VBAC after 40
weeks gestation, advanced maternal age, short stature and a male infant are also
independently associated with a decreased likelihood of VBAC success 26;28;29.
Several pre-admission and admission based multivariate models have been developed to
predict the likelihood of VBAC success 26;30-33. However, their usefulness in clinical practice
remains to be determined.

Women considering trial of VBAC should be counselled that the absolute risk of uterine
rupture is extremely low (74 per 10,000).

Uterine rupture in an unscarred uterus is extremely rare at 2 per 10,000 deliveries, and this
risk is mainly confined to multiparous women in labour 34. The NICHD study reported the
overall risk for symptomatic uterine rupture at term was 74 per 10,000 trials of VBAC 14.
There was zero risk in women undergoing ERCS 14. Studies with differing methodological
designs and definitions of scar rupture report similar estimates for risk of uterine rupture in
trial of VBAC: systematic and non-systematic reviews of 39 24, 43 13 and 62 23 per 10,000;
retrospective studies of 35 35 and 65 22 per 10,000. Although a rare outcome, uterine rupture is
associated with significant maternal and perinatal morbidity and perinatal mortality (see
below).

Women considering trial of VBAC should be counselled that there is probably a small
increased risk of blood transfusion and endometritis compared to ERCS, and that the
absolute risks of serious adverse effects (e.g. hysterectomy, thromboembolic disease or
maternal mortality) are extremely low.

Although absolute risks remain small, women attempting trial of VBAC compared to ERCS
are at greater risk of blood transfusion requirement (1.7% vs.1.0%) and endometritis (2.9%
vs. 1.8%)14. There was no significant difference between trial of VBAC and ERCS groups in
relation to hysterectomy (23 per 10,000 vs. 30 per 10,000), thromboembolic disease (4 per
10,000 vs. 6 per 10,000) or maternal death (17/100,000 vs. 44/100,000)14. However, this
comparison is undermined by the fact that the group delivered by ERCS in that study
included women in whom an attempt at VBAC was absolutely or relatively contraindicated,
e.g. due to placenta praevia, high numbers of previous caesarean deliveries or maternal
disease. The presence of these conditions may have led to an over-estimate of the risk of
adverse outcomes associated with ERCS. Nonetheless, the study clearly indicates that the
absolute risks of severe maternal adverse effects of attempting VBAC are extremely small.
Maternal death related to uterine rupture in trial of VBAC is exceedingly rare in the
developed world and is confined to case reports 22;36.

Women considering trial of VBAC should be counselled that this decision probably
carries a very small additional risk of perinatal death compared with ERCS but that the
risk of such a loss is comparable to the risk for women having their first birth.

In the NICHD study14, perinatal mortality at term was significantly greater among women attempting VBAC than women delivered by ERCS. Overall perinatal mortalities for trial of VBAC vs. ERCS respectively were 32 per 10,000 vs. 13 per 10,000 (RR 2.40, 95% CI 1.43 to 4.01) and perinatal mortalities after excluding fetal malformation were 24 per 10,000 vs. 9.3 per 10,000 (RR 2.52, 95% CI 1.37-4.62). Approximately 70% of the perinatal deaths in attempted VBAC were due to antepartum stillbirth. Approximately 40% of these stillbirths had no congenital abnormality and occurred at or after 39 weeks gestation and may, therefore, have been prevented by performing ERCS at 39 weeks. The absolute risk of antepartum stillbirth at or after 39 weeks among women with one prior caesarean section is approximately 10 per 10,000 14;37. In the NICHD study, rates of delivery-related perinatal death were very low: 4 per 10,000 for women attempting VBAC and 1.4 per 10,000 for ERCS 14. A report of data for the whole of Scotland demonstrated higher overall rates of delivery-related perinatal death associated with attempted VBAC of 12.9 per 10,000 whereas the risk of death associated with ERCS was comparable to the US study at 1.1 per 10,000 21. The reason for the higher rate of delivery-
related deaths among women attempting VBAC in Scotland may reflect the fact that these
were population-based data whereas the US data were exclusively from tertiary centres.
Consistent with this interpretation, a further study of data from Scotland demonstrated a
lower risk of perinatal death due to uterine rupture in larger centres 35.
Accepting the limitations of using these observational data, a reasonable summary is that
attempting VBAC carries an approximately 10 per 10,000 additional risk of an antepartum
stillbirth and, if the attempt is conducted in a large centre, an approximately 4 per 10,000 risk
of delivery-related perinatal death. Women should be counselled that it is possible that these
risks may be reduced by ERCS but direct evidence of this is lacking. It may be helpful to
emphasise to women that the absolute risks of both antepartum stillbirth and delivery-related
perinatal death among women attempting VBAC are comparable to the risks for nulliparous
women 21;38.
Women considering trial of VBAC should be counselled that this decision probably
carries a very small additional risk of the infant developing hypoxic ischaemic
encephalopathy. The effect of the decision on the long term outcome for the infant is
unknown.

The incidence of intrapartum hypoxic ischaemic encephalopathy (HIE) at term is significantly
greater in trial of VBAC (7.8 per 10,000) compared to ERCS (zero rate)14. Approximately
half of the increased risk in trial of VBAC arises due to the additional risk of HIE caused by
uterine rupture (4.6 per 10,000)14. The definition used and distribution of severity of HIE is
not stated in the NICHD study 14. Severe neonatal metabolic acidosis (pH<7.00) occurred in
33% of term uterine ruptures 14. There is no information comparing long term outcome, such
as cerebral palsy, among women attempting VBAC and those delivered by ERCS. Given that
cerebral palsy following term birth is very rare (approximately 10 per 10,000) and that most
cases are thought to be unrelated to mode of delivery, appropriate analysis of this question
would require a scale involving hundreds of thousands of women. No adequate study has
currently been reported.

Women considering trial of VBAC should be counselled that an attempt at vaginal birth
probably reduces the risk that the infant will develop respiratory problems in the
neonatal period.

Three observational studies, pooling data from around 90,000 deliveries, have shown an
increased risk of neonatal respiratory morbidity in term infants delivered by elective
caesarean (3.5%-3.7%) compared to vaginal delivery (0.53%-1.4%) 39-41. The NICHD study
14 (n=30,352 deliveries) reported a similar trend in women with prior caesarean section,
where the incidence of TTN in ERCS vs. trial of VBAC was 3.6% vs. 2.6% (RR 1.40, 95%
CI 1.23-1.59; NNT -98). These rates concur with rates of TTN derived from a smaller data set
that examined women with prior caesarean section (2 studies, n=4,478 deliveries) of 2.4%-
6% vs. 1.3%-3% 41;42 for ERCS vs. trial of VBAC respectively. The NICHD study did not
report rates of RDS, however the smaller data set reported RDS as 0.4%-0.6% vs. 0%-0.05%
for ERCS vs. trial of VBAC respectively 41;42.
Women considering trial of VBAC should be counselled that the additional risk of
respiratory problems in the neonatal period associated with ERCS can be reduced – but
not eliminated - by delaying the procedure until 39 weeks.

Evidence from observational studies 39-41 and a recently published trial 43 has shown a
beneficial effect on reducing respiratory morbidity by delaying elective caesarean section to
at least 39 weeks. The trial reported respiratory morbidity was11.4%, 6.2% and 1.5% at 37,
38 and 39 weeks gestation respectively 43. Furthermore, the trial 43 demonstrated an
approximate 50% reduction in respiratory morbidity (for both TTN and RDS components) by
administering prophylactic betamethasone to elective caesarean deliveries beyond 37 weeks
(steroid vs control; 2.4% vs 5.1%; RR 0.46, 95% CI 0.23-0.93), and this treatment effect was
still apparent at 39 weeks (steroid vs control; 0.6% vs 1.5%). The routine use of prophylactic
betamethasone in ERCS is beyond the scope of this guideline.

Women considering mode of delivery who are eligible for VBAC should be counselled
that the risk of severe anaesthetic complications is very low irrespective of the chosen
mode of delivery.

Anaesthetic procedure-related complications are extremely rare. Of the women undergoing
caesarean section (emergency and elective) in the NICHD study (n=37,142), 93% received a
regional anaesthetic and only 3% of regional procedures failed. There was one maternal death
(2.7 per 100,000) attributed to an anaesthetic problem (failed intubation) 44.
Women considering trial of VBAC should be counselled that the decision to have an
ERCS may increase the risk of serious complications in future pregnancies

Overall, placenta praevia occurs in 5 per 1000 deliveries 45 and placenta accreta between
0.25-2 per 1000 deliveries. All women with one caesarean section have an increased risk of
placenta praevia (RR 4.5, 95% CI 3.6-5.5) and placenta accreta (complicating 10-24% of
praevias) relative to women with an unscarred uterus46. However, repeat caesarean deliveries
will increase the relative risk of placenta praevia, placenta accreta and consequent
hysterectomy in subsequent pregnancies, as the relationship between number of prior
caesareans and these outcomes is approximately linear 46-49. Major maternal morbidity
(hysterectomy, haemorrhage, viscus injury, dense adhesions) rises with each successive
caesarean section, and is particularly associated with the presence of placental praevia or
placenta accreta 48;50;51. A retrospective study of approximately 3000 women from Saudi
Arabia showed a linear increase in the risk of bladder injury (0.3%, 0.8%, 2.4%),
hysterectomy (0.1%, 0.7%, 1.2%) and transfusion requirement (7.2%, 7.9%, 14.1%) with a
history of two, three and five caesarean sections respectively 48.
Women considering trial of VBAC should be counselled that there is only limited
evidence on the safety and efficacy of trial of VBAC in twin gestation, fetal macrosomia
and short inter-delivery interval.

Study sample sizes are underpowered to provide reliable evidence suitable for any clinical
practice recommendation in relation to twin gestation, fetal macrosomia and short inter-
delivery interval.
Twin Gestation
The US Cohort study 52 (n=186 twins), US retrospective study53 (n=535 twins) and a review
17 (7 studies, n=233 twins) have reported similar successful rates of VBAC in twin
pregnancies to that in singleton pregnancies (65%-84%). Women who attempted a trial of
VBAC with twins had no increased risk of major maternal morbidity or uterine rupture
compared to trials of VBAC in singleton gestations 52;53.
Fetal Macrosomia
A review 17 of four retrospective studies has reported a significantly decreased likelihood of
successful trial of VBAC for pregnancies with infants weighing 4000g or more (55-67%)
compared to smaller infants (77-83%). There is no increased risk of uterine rupture, except in
the subgroup of women without a prior vaginal delivery 54. However, in reality, birth weight
is unknown, the evidence is not robust, and it is difficult to incorporate suspected birth weight
data into antenatal counselling.
Short inter-delivery interval
Three observational studies of limited size 55-57 have shown a two-to-three fold increased risk
of uterine scar rupture for women with a short inter-delivery interval (below 15-24 months)
from their previous caesarean section.

8. Conduct of an attempt at VBAC

Trial of VBAC should be conducted in a suitably staffed and equipped delivery suite
with resources for immediate caesarean section and neonatal resuscitation

Obstetric, midwifery, anaesthetic, operating theatre and haematological support should be
available throughout trial of VBAC and ERCS. A retrospective study of Canadian data
showed that the relative risk of uterine rupture when comparing trial of VBAC with ERCS
increased two fold in low-volume obstetric units (<500 births per year) than high-volume
(>500 births per year) units, even though lower volume units had lower-risk obstetric
population 22. A retrospective study on Scottish data showed that trial of VBAC in low-
volume hospitals (<3000 births/year) was not associated with an increased risk of uterine
rupture overall but was associated with an increased risk of uterine rupture that led to
perinatal death 35. It is likely that the availability of resources for immediate delivery and
neonatal resuscitation may reduce the risk of uterine rupture to the infant.

Induction of labour is associated with increased risks of uterine rupture and caesarean
section. Consequently, the decision, timing and method of induction of labour should be
consultant-led and the induction process should occur on labour ward.

For all methods of induction, the absolute risk of uterine rupture was 101 per 10,000 (1%) in
the NICHD study 14 and 82 per 10,000 (0.8%) in a Canadian data set 22. This equated to
around a two-fold higher risk of uterine rupture than women in spontaneous labour for each
respective study.
Particular caution should be applied to women with an unfavourable cervix who require
prostaglandin priming of the cervix.

Two studies have shown higher risks of uterine rupture with prostaglandin than non-prostaglandin based methods of induction 14;35. In the NICHD study, prostaglandin based induction incurred a non-significantly higher uterine rupture risk than mechanical induction methods (e.g. insertion of intracervical Foley catheter) (140 per 10,000 vs. 89 per 10,000) 14.
A retrospective analysis of approximately 36,000 women attempting VBAC in Scotland
which included approximately 4,600 women having prostaglandin induction, showed that
induction of labour with prostaglandin, but not other methods, was independently associated
with an increased risk of uterine rupture leading to perinatal death (11 per 10,000 inductions)
35. This risk was three-fold higher than the perinatal death rate due to uterine rupture in non-
prostaglandin based inductions (4.5 per 10,000 inductions). This compares to 6 per 10,000
risk of perinatal death in women with an unscarred uterus induced by prostaglandin identified
by a Cochrane review.58 It is currently unclear whether the association between PGE2 and
uterine rupture is a specific pharmacological effect of the drug or whether it is a marker of
women with an unfavourable cervix59. Use of prostaglandin induction is associated with a
likelihood ratio for caesarean section of 1.37 equating to an increased risk of emergency
caesarean section from 25% to 35% 26. Systematic reviews 60-62 have shown there is limited
quality evidence on induction methods and their outcomes (4 RCTs, n=137), and only limited
analysis of induction methods was performed by the NICHD study14. However, some women
may be prepared to accept the additional risk associated with prostaglandin induction (e.g.
those who are planning many future pregnancies) in view of the advantages of a successful
VBAC.
Epidural anaesthesia is not contraindicated in an attempt at VBAC
Trial of VBAC success rates are similar in women who receive epidural analgesia to those
that receive alternative methods of analgesia63. Furthermore, epidural analgesia does not
significantly mask the signs and symptoms associated with uterine rupture 64. A retrospective
comparative study showed that within the trial of VBAC group, infants of mothers who
received epidural analgesia were more likely to be subjected to diagnostic tests and
therapeutic interventions (including sepsis evaluation and antibiotic treatment) compared to
infants from a matched no-epidural analgesia group 65.

Women should be advised to have continuous electronic fetal monitoring following onset
of uterine contractions for the duration of trial of VBAC.

An abnormal CTG is the most consistent finding in uterine rupture and is present in 55%-87%
of these events13. Moreover, continuous electronic fetal monitoring is generally used among
women attempting VBAC and thus the estimates of risk of both lethal and non-lethal
perinatal asphyxia associated with VBAC are in this context. The relative and absolute risks
of severe adverse events in the absence of continuous electronic fetal monitoring are
unknown.

There is insufficient evidence to support the use of intrauterine pressure catheters in the
early detection of uterine scar rupture

Observational studies have shown intrauterine pressure catheters are not always reliable 66
and do not add significant additional ability to predict uterine rupture over clinical and CTG
surveillance 67-70. Furthermore, intrauterine catheter insertion may be associated with risk 71.

Intrapartum care should be vigilant for the characteristic symptoms and signs
suggesting uterine scar dehiscence or rupture.

Early diagnosis of uterine scar dehiscence or rupture followed by expeditious laparotomy and resuscitation is essential to reduce associated morbidity and mortality. There is no single pathogonomic clinical feature indicating uterine rupture but the presence of any of the following peripartum is indicative of this event. The diagnosis is ultimately confirmed at emergency caesarean section or postpartum laparotomy. 2. Severe abdominal pain, especially if persisting between contractions 3. Acute onset scar tenderness 4. Abnormal vaginal bleeding or haematuria 5. Abrupt cessation of uterine activity 6. Inefficient uterine activity 7. Maternal 8. Loss of station of the presenting part
Women should be counselled regarding the 2-fold increased risk of uterine rupture and
1.5-fold increased risk of caesarean section in augmented compared to non-augmented
labours. Therefore, the use of oxytocin augmentation should be a consultant-led
decision.

Augmentation of labour among women with an unscarred uterus is associated with an extremely low risk of uterine rupture at 5 per 10,000 34. Among women attempting VBAC, the risk of uterine rupture in those with non-augmented labour was 36 per 10,000 and in those having labour augmented was 87 per 10,00014. A systematic review61 of seven observational studies showed that oxytocin given to induce and/or augment labour increased the risk of caesarean section compared to non-augmented spontaneous labour by around 1.5 fold (32% [range 18-44] vs. 20% [range 11-35]). These additional risks in augmented trial of VBAC mean that: 1) Although augmentation is not contraindicated it should only be commenced after careful obstetric assessment, patient counselling and by a consultant-led decision. 2) Frequent serial cervical assessment is necessary to show adequate cervicometric progress and fetal head descent to permit the augmentation process to continue. Inefficient uterine activity in women with prior caesarean may be a sign that uterine rupture has occurred or is imminent. The administration of oxytocin in this situation, or where there is failure to progress despite adequate augmentation, may seriously compound a pre-existing problem.
There are no data on the maximum safe interval for vaginal examinations to assess progress
in augmented labour in women with a previous caesarean. Therefore, at the time of the
consultant decision to augment a labour with oxytocin, a clear plan for further cervical
assessment should also be documented along with the criteria for discontinuing the attempt at
vaginal birth.
9. Auditable standards
Standards for audit of practice could include the following:
Use of continuous electronic fetal monitoring during conduct of VBAC.

Standards for audit of documentation could include the following:

Documented discussion of risks and benefits of VBAC
Documentation of consultant involvement in decisions to induce labour or augment labour
Documentation of plan in the event of oxytocin augmentation of labour in VBAC

10. Future research

Development, validation and pragmatic clinical evaluation of a scoring system to identify women at high or low risk of a failed VBAC that is antenatally and/or intrapartum based. The clinical effectiveness of differing induction and augmentation regimens, perhaps individualised according to clinical features rather than standard proscribed strategies Identify if there are differences in long-term maternal and infant outcomes between trial of VBAC and ERCS e.g. subfertility, depression, pelvic floor dysfunction, incontinence, psychosexual problems, respiratory illness, and neurodevelopmental disorders. Preference-based studies to identify which factors impact most on women accepting or declining trial of VBAC (e.g. patient information leaflet, previous childbirth experiences, desired family size, understanding the risk analysis during counselling)72-78. Assess patient satisfaction79;80, quality of life measures and health-state utilities in women following VBAC and ERCS to undertake robust economic modelling assessments.
11. Pending relevant trials

• ACTOBAC- A Collaborative Trial of Birth After Caesarean, No ISCRTN, Prof C
Crowther, Adelaide, Australia. Colleagues have raised ethical and feasibility concerns with such a trial 81 • The Twin Birth Study- a multicentre RCT comparing planned caesarean section with planned vaginal birth for twins at 32-38 weeks gestation, ISRCTN 74420086, Dr J Barrett, Toronto, Canada • DiAMOND-Decision Aids for Mode Of Next Delivery, ISRCTN 84367722, Dr A • CAESAR-Caesarean Section Surgical Techniques , ISRCTN 11849611, Dr P Brocklehurst, National Perinatal Epidemiology Unit, Oxford, UK The Parliamentary Office of Science and Technology. Caesarean Sections. PostNote. Report Number 184. http://www.parliament.uk/post/pn184.pdf. 2002. (2) Menacker F. Trends in cesarean rates for first births and repeat cesarean rates for low-risk women: United States, 1990-2003. Natl Vital Stat Rep 2005; 54(4):1-8. (3) Liu S, Rusen ID, Joseph KS, Liston R, Kramer MS, Wen SW et al. Recent trends in caesarean delivery rates and indications for caesarean delivery in Canada. Journal of Obstetrics & Gynaecology Canada: JOGC 2004; 26(8):735-742. (4) Black C, Kaye JA, Jick H. Cesarean delivery in the United Kingdom: time trends in the general practice research database. Obstet Gynecol 2005; 106(1):151-155. (5) Yeh J, Wactawski-Wende J, Shelton JA, Reschke J. Temporal trends in the rates of trial of labor in low-risk pregnancies and their impact on the rates and success of vaginal birth after cesarean delivery. Am J Obstet Gynecol 2006; 194(1):144. (6) RCOG. Caesarean Section: The National Sentinel Audit Report. 2001. Royal College of Obstetricians and Gynaecologists, London, UK. (7) ACOG Committee on Obstetric Practice. Committee opinion. Induction of labor for vaginal birth after cesarean delivery. Obstetrics & Gynecology 2002; 99(4):679-680. (8) ACOG Committee on Obstetric Practice. ACOG Practice Bulletin #54: vaginal birth after previous cesarean. Obstetrics & Gynecology 2004; 104(1):203-212. (9) SOGC. The Society of Obstetricians and Gynaecologists of Canada. SOGC Clinical Practice Guidelines. Guidelines for vaginal birth after previous caesarean birth. Number 155 (Replaces guideline Number 147), February 2005. Int J Gynaecol Obstet 2005; 89(3):319-331. (10) Guise JM, McDonagh MS, Hashima J, Kraemer DF, Eden KB, Berlin M et al. Vaginal birth after cesarean (VBAC). Evidence Report: Technology Assessment (Summary) 2003;(71):1-8. (11) Dodd JM, Crowther CA, Huertas E, Guise JM, Horey D. Planned elective repeat caesarean section versus planned vaginal birth for women with a previous caesarean birth. Cochrane Database Syst Rev 2006;(4):CD004224. (12) Guise JM, Berlin M, McDonagh M, Osterweil P, Chan B, Helfand M. Safety of vaginal birth after cesarean: a systematic review. Obstetrics & Gynecology 2004; 103(3):420-429. (13) Guise JM, McDonagh MS, Osterweil P, Nygren P, Chan BK, Helfand M. Systematic review of the incidence and consequences of uterine rupture in women with previous caesarean section. BMJ 2004; 329(7456):19-25. (14) Landon MB, Hauth JC, Leveno KJ, Spong CY, Leindecker S, Varner MW et al. Maternal and perinatal outcomes associated with a trial of labor after prior cesarean delivery. New England Journal of Medicine 2004; 351(25):2581-2589. (15) Lieberman E, Ernst EK, Rooks JP, Stapleton S, Flamm B. Results of the national study of vaginal birth after cesarean in birth centers. Obstetrics & Gynecology 2004; 104(5 Pt 1):933-942. (16) Macones GA, Cahill A, Pare E, Stamilio DM, Ratcliffe S, Stevens E et al. Obstetric outcomes in women with two prior cesarean deliveries: is vaginal birth after cesarean delivery a viable option? Am J Obstet Gynecol 2005; 192(4):1223-1228. (17) Guise JM, Hashima J, Osterweil P. Evidence-based vaginal birth after Caesarean section. Best Pract Res Clin Obstet Gynaecol 2005; 19(1):117-130. (18) Spaans WA, van der Vliet LM, Roell-Schorer EA, Bleker OP, van Roosmalen J. Trial of labour after two or three previous caesarean sections. European Journal of Obstetrics, Gynecology, & Reproductive Biology 2003; 110(1):16-19. (19) Caughey AB, Shipp TD, Repke JT, Zelop CM, Cohen A, Lieberman E. Rate of uterine rupture during a trial of labor in women with one or two prior cesarean deliveries. American Journal of Obstetrics & Gynecology 1999; 181(4):872-876. (20) Miller DA, Diaz FG, Paul RH. Vaginal birth after cesarean: a 10-year experience. (21) Smith GC, Pell JP, Cameron AD, Dobbie R. Risk of perinatal death associated with labor after previous cesarean delivery in uncomplicated term pregnancies. JAMA 2002; 287(20):2684-2690. (22) Wen SW, Rusen ID, Walker M, Liston R, Kramer MS, Baskett T et al. Comparison of maternal mortality and morbidity between trial of labor and elective cesarean section among women with previous cesarean delivery. American Journal of Obstetrics & Gynecology 2004; 191(4):1263-1269. (23) Chauhan SP, Martin JN, Jr., Henrichs CE, Morrison JC, Magann EF. Maternal and perinatal complications with uterine rupture in 142,075 patients who attempted vaginal birth after cesarean delivery: A review of the literature. American Journal of Obstetrics & Gynecology 2003; 189(2):408-417. (24) Mozurkewich EL, Hutton EK. Elective repeat cesarean delivery versus trial of labor: a meta-analysis of the literature from 1989 to 1999. American Journal of Obstetrics & Gynecology 2000; 183(5):1187-1197. (25) Landon MB, Leindecker S, Spong CY, Hauth JC, Bloom S, Varner MW et al. The MFMU Cesarean Registry: factors affecting the success of trial of labor after previous cesarean delivery. American Journal of Obstetrics & Gynecology 2005; 193(3 Pt 2):1016-1023. (26) Smith GC, White IR, Pell JP, Dobbie R. Predicting cesarean section and uterine rupture among women attempting vaginal birth after prior cesarean section. PLoS Med 2005; 2(9):e252. (27) Gyamfi C, Juhasz G, Gyamfi P, Stone JL. Increased success of trial of labor after previous vaginal birth after cesarean. Obstetrics & Gynecology 2004; 104(4):715-719. (28) Bujold E, Hammoud AO, Hendler I, Berman S, Blackwell SC, Duperron L et al. Trial of labor in patients with a previous cesarean section: does maternal age influence the outcome? American Journal of Obstetrics & Gynecology 2004; 190(4):1113-1118. (29) Coassolo KM, Stamilio DM, Pare E, Peipert JF, Stevens E, Nelson DB et al. Safety and efficacy of vaginal birth after cesarean attempts at or beyond 40 weeks of gestation. Obstet Gynecol 2005; 106(4):700-706. (30) Flamm BL, Geiger AM. Vaginal birth after cesarean delivery: an admission scoring system. Obstetrics & Gynecology 1997; 90(6):907-910. (31) Macones GA, Hausman N, Edelstein R, Stamilio DM, Marder SJ. Predicting outcomes of trials of labor in women attempting vaginal birth after cesarean delivery: a comparison of multivariate methods with neural networks. American Journal of Obstetrics & Gynecology 2001; 184(3):409-413. (32) Durnwald C, Mercer B. Vaginal birth after Cesarean delivery: predicting success, risks of failure. Journal of Maternal-Fetal & Neonatal Medicine 2004; 15(6):388-393. (33) Hashima JN, Eden KB, Osterweil P, Nygren P, Guise JM. Predicting vaginal birth after cesarean delivery: a review of prognostic factors and screening tools. American Journal of Obstetrics & Gynecology 2004; 190(2):547-555. (34) Ofir K, Sheiner E, Levy A, Katz M, Mazor M. Uterine rupture: risk factors and pregnancy outcome. American Journal of Obstetrics & Gynecology 2003; 189(4):1042-1046. (35) Smith GC, Pell JP, Pasupathy D, Dobbie R. Factors predisposing to perinatal death related to uterine rupture during attempted vaginal birth after caesarean section: retrospective cohort study. BMJ 2004; 329(7462):375. (36) Farmer RM, Kirschbaum T, Potter D, Strong TH, Medearis AL. Uterine rupture during trial of labor after previous cesarean section. Am J Obstet Gynecol 1991; 165(4 Pt 1):996-1001. (37) Smith GC, Pell JP, Dobbie R. Caesarean section and risk of unexplained stillbirth in subsequent pregnancy. Lancet 2003; 362(9398):1779-1784. (38) Smith GC. Life-table analysis of the risk of perinatal death at term and post term in singleton pregnancies. Am J Obstet Gynecol 2001; 184(3):489-496. (39) Levine EM, Ghai V, Barton JJ, Strom CM. Mode of delivery and risk of respiratory diseases in newborns. Obstet Gynecol 2001; 97(3):439-442. (40) Morrison JJ, Rennie JM, Milton PJ. Neonatal respiratory morbidity and mode of delivery at term: influence of timing of elective caesarean section. Br J Obstet Gynaecol 1995; 102(2):101-106. (41) Richardson BS, Czikk MJ, daSilva O, Natale R. The impact of labor at term on measures of neonatal outcome. Am J Obstet Gynecol 2005; 192(1):219-226. (42) Hook B, Kiwi R, Amini SB, Fanaroff A, Hack M. Neonatal morbidity after elective repeat cesarean section and trial of labor. Pediatrics 1997; 100(3 Pt 1):348-353. (43) Stutchfield P, Whitaker R, Russell I. Antenatal betamethasone and incidence of neonatal respiratory distress after elective caesarean section: pragmatic randomised trial. ASTECS study. BMJ 2005; 331(7518):662. (44) Bloom SL, Spong CY, Weiner SJ, Landon MB, Rouse DJ, Varner MW et al. Complications of anesthesia for cesarean delivery. Obstet Gynecol 2005; 106(2):281-287. (45) Faiz AS, Ananth CV. Etiology and risk factors for placenta previa: an overview and meta-analysis of observational studies. J Matern Fetal Neonatal Med 2003; 13(3):175-190. (46) Ananth CV, Smulian JC, Vintzileos AM. The association of placenta previa with history of cesarean delivery and abortion: a metaanalysis. Am J Obstet Gynecol 1997; 177(5):1071-1078. (47) Miller DA, Chollet JA, Goodwin TM. Clinical risk factors for placenta previa- placenta accreta. Am J Obstet Gynecol 1997; 177(1):210-214. (48) Makoha FW, Felimban HM, Fathuddien MA, Roomi F, Ghabra T. Multiple cesarean section morbidity. Int J Gynaecol Obstet 2004; 87(3):227-232. (49) Wu S, Kocherginsky M, Hibbard JU. Abnormal placentation: twenty-year analysis. Am J Obstet Gynecol 2005; 192(5):1458-1461. (50) Lynch CM, Kearney R, Turner MJ. Maternal morbidity after elective repeat caesarean section after two or more previous procedures. European Journal of Obstetrics, Gynecology, & Reproductive Biology 2003; 106(1):10-13. (51) Uygur D, Gun O, Kelekci S, Ozturk A, Ugur M, Mungan T. Multiple repeat caesarean section: is it safe? Eur J Obstet Gynecol Reprod Biol 2005; 119(2):171-175. (52) Varner MW, Leindecker S, Spong CY, Moawad AH, Hauth JC, Landon MB et al. The Maternal-Fetal Medicine Unit cesarean registry: trial of labor with a twin gestation. Am J Obstet Gynecol 2005; 193(1):135-140. (53) Cahill A, Stamilio DM, Pare E, Peipert JP, Stevens EJ, Nelson DB et al. Vaginal birth after cesarean (VBAC) attempt in twin pregnancies: is it safe? Am J Obstet Gynecol 2005; 193(3 Pt 2):1050-1055. (54) Elkousy MA, Sammel M, Stevens E, Peipert JF, Macones G. The effect of birth weight on vaginal birth after cesarean delivery success rates. American Journal of Obstetrics & Gynecology 2003; 188(3):824-830. (55) Bujold E, Mehta SH, Bujold C, Gauthier RJ. Interdelivery interval and uterine rupture. American Journal of Obstetrics & Gynecology 2002; 187(5):1199-1202. (56) Esposito MA, Menihan CA, Malee MP. Association of interpregnancy interval with uterine scar failure in labor: a case-control study. American Journal of Obstetrics & Gynecology 2000; 183(5):1180-1183. (57) Shipp TD, Zelop CM, Repke JT, Cohen A, Lieberman E. Interdelivery interval and risk of symptomatic uterine rupture. Obstetrics & Gynecology 2001; 97(2):175-177. (58) Kelly AJ, Kavanagh J, Thomas J. Vaginal prostaglandin (PGE2 and PGF2a) for induction of labour at term. Cochrane Database Syst Rev 2006;(2):CD003101. (59) Bujold E, Blackwell SC, Hendler I, Berman S, Sorokin Y, Gauthier RJ. Modified Bishop's score and induction of labor in patients with a previous cesarean delivery. American Journal of Obstetrics & Gynecology 2004; 191(5):1644-1648. (60) NICE. National Institute of Clinical Excellence. RCOG Induction of labour. Evidence-based Clinical guideline Number 9. 2001. National Institute of Clinical Excellence. (61) McDonagh MS, Osterweil P, Guise JM. The benefits and risks of inducing labour in patients with prior caesarean delivery: a systematic review. BJOG 2005; 112(8):1007-1015. (62) Dodd J, Crowther C. Induction of labour for women with a previous Caesarean birth: a systematic review of the literature. Aust N Z J Obstet Gynaecol 2004; 44(5):392-395. (63) Sakala EP, Kaye S, Murray RD, Munson LJ. Epidural analgesia. Effect on the likelihood of a successful trial of labor after cesarean section. J Reprod Med 1990; 35(9):886-890. Critchley LA, Gin T. Uterine rupture and epidural analgesia during trial of labour. Anaesthesia 1997; 52(5):486-488. (65) Fisler RE, Cohen A, Ringer SA, Lieberman E. Neonatal outcome after trial of labor compared with elective repeat cesarean section. Birth 2003; 30(2):83-88. (66) Devoe LD, Croom CS, Youssef AA, Murray C. The prediction of "controlled" uterine rupture by the use of intrauterine pressure catheters. Obstet Gynecol 1992; 80(4):626-629. (67) Arulkumaran S, Chua S, Ratnam SS. Symptoms and signs with scar rupture--value of uterine activity measurements. Aust N Z J Obstet Gynaecol 1992; 32(3):208-212. (68) Beckley S, Gee H, Newton JR. Scar rupture in labour after previous lower uterine segment caesarean section: the role of uterine activity measurement. Br J Obstet Gynaecol 1991; 98(3):265-269. Alfirevic Z. Uterine rupture after induction of labour in women with previous caesarean section. BJOG 2005; 112(4):451-455. (70) Rodriguez MH, Masaki DI, Phelan JP, Diaz FG. Uterine rupture: are intrauterine pressure catheters useful in the diagnosis? Am J Obstet Gynecol 1989; 161(3):666-669. (71) Madanes AE, David D, Cetrulo C. Major complications associated with intrauterine pressure monitoring. Obstet Gynecol 1982; 59(3):389-391. (72) Eden KB, Hashima JN, Osterweil P, Nygren P, Guise JM. Childbirth preferences after cesarean birth: a review of the evidence. Birth 2004; 31(1):49-60. (73) Horey D, Weaver J, Russell H. Information for pregnant women about caesarean birth. Cochrane Database Syst Rev 2004;(1):CD003858. (74) Gamble JA, Creedy DK. Women's preference for a cesarean section: incidence and associated factors. Birth 2001; 28(2):101-110. (75) Shorten A, Shorten B, Keogh J, West S, Morris J. Making choices for childbirth: a randomized controlled trial of a decision-aid for informed birth after cesarean. Birth 2005; 32(4):252-261. (76) Mankuta DD, Leshno MM, Menasche MM, Brezis MM. Vaginal birth after cesarean section: trial of labor or repeat cesarean section? A decision analysis. American Journal of Obstetrics & Gynecology 2003; 189(3):714-719. (77) Pare E, Quinones JN, Macones GA. Vaginal birth after caesarean section versus elective repeat caesarean section: assessment of maternal downstream health outcomes. BJOG 2006; 113(1):75-85. (78) Dodd J, Pearce E, Crowther C. Women's experiences and preferences following Caesarean birth. Aust N Z J Obstet Gynaecol 2004; 44(6):521-524. C. Comparison of maternal satisfaction following vaginal delivery after caesarean section and caesarean section after previous vaginal delivery. Eur J Obstet Gynecol Reprod Biol 2005; 121(1):56-60. (80) Cleary-Goldman J, Cornelisse K, Simpson LL, Robinson JN. Previous cesarean delivery: understanding and satisfaction with mode of delivery in a subsequent pregnancy in patients participating in a formal vaginal birth after cesarean counseling program. Am J Perinatol 2005; 22(4):217-221. (81) Ecker JL. Once a pregnancy, always a cesarean? Rationale and feasibility of a randomized controlled trial. American Journal of Obstetrics & Gynecology 2004; 190(2):314-318.
Classification of Evidence Levels
Ia Evidence obtained from meta-analysis of randomised controlled trials.
Ib Evidence obtained from at least one randomised controlled trial.
IIa Evidence obtained from at least one well-designed controlled study without
randomisation.
IIb Evidence obtained from at least one other type of well-designed quasi-experimental study.
III Evidence obtained from well-designed non-experimental descriptive studies, such as
comparative studies, correlation studies and case studies.
IV Evidence obtained from expert committee reports or opinions and/or clinical experience of
respected authorities.
Grades of Recommendations
Requires at least one randomised controlled trial as part of a body of literature of overall good quality and consistency addressing the specific recommendation. (Evidence levels Ia, Ib) Requires the availability of well controlled clinical studies but no randomised clinical trials on the topic of recommendations. (Evidence levels IIa, IIb, III) Requires evidence obtained from expert committee reports or opinions and/or clinical experiences of respected authorities. Indicates an absence of directly applicable clinical studies of good quality. (Evidence level IV) Good Practice Point
Recommended best practice based on the clinical experience of the guideline This Guideline was produced on behalf of the Guidelines and Audit Committee of the Royal College of
Obstetricians and Gynaecologists by:
Professor G C S Smith MRCOG, Dr R Varma MRCOG, and Dr J K Gupta FRCOG,
and peer reviewed by:
The final version is the responsibility of the Guidelines and Audit Committee of the RCOG.=

Source: http://www.bellitti.it/Delivery_after_previous_caesarean_birth.pdf

auroraivf.ca

Clomiphene (also called Serophene or Clomid) is an oral fertility medication which is used to increase the number of eggs which are released at the time of ovulation. Intrauterine insemination (or “IUI”) is a fertility procedure in which the male partner gives a sperm sample which is then prepared by the lab to concentrate the best quality sperm into a small droplet. If donor sperm is being

foreignmed.com

The role of blood pressure lowering before and after strokeGeoffrey A. Donnana, Stephen M. Davisb and Amanda ThriftaElevated blood pressure is one of the most potent risk factorsAcute Candesartan Cilexetil Evaluation in Stroke Survivorsfor first ever and recurrent stroke as well as influencing earlyoutcome after acute stroke. There have been a number ofsignificant randomized controlled trials

Copyright © 2010-2014 Drugstore Pdf Search